<- Go Home

Laboratorios Farmaceuticos Rovi, S.A.

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, aseptic filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Its products are used for cardiology, osteoarticular/women’s health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.

Market Cap

EUR 3.3B

Volume

98.6K

Cash and Equivalents

EUR 46.1M

EBITDA

EUR 194.5M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

EUR 467.4M

Profit Margin

62.40%

52 Week High

EUR 80.20

52 Week Low

EUR 45.52

Dividend

1.45%

Price / Book Value

5.84

Price / Earnings

24.87

Price / Tangible Book Value

6.17

Enterprise Value

EUR 3.4B

Enterprise Value / EBITDA

16.88

Operating Income

EUR 172.7M

Return on Equity

25.01%

Return on Assets

12.50

Cash and Short Term Investments

EUR 47.7M

Debt

EUR 129.3M

Equity

EUR 574.7M

Revenue

EUR 749.0M

Unlevered FCF

EUR 9.0M

Sector

Pharmaceuticals

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches